Coronavirus, covid-19 | The Oxford vaccine needs more testing



[ad_1]

The Oxford vaccine developed by AstraZeneca needs further study, the company said Thursday. The vaccine is among the three most relevant for Norway and Europe.

The Oxford vaccine developed by AstraZeneca needs further study, the company said Thursday. The vaccine is among the three most relevant for Norway and Europe.

– We’ve figured out what looks like better efficiency, but this needs to be confirmed, AstraZeneca CEO Pascal Soriot says in a Bloomberg article Thursday.

Also read: Doctors believe that people should be warned about the side effects of the coronary vaccine: – This will not be a dance of roses

Soriot says the additional studies will likely have no consequences for the approval of the vaccine in the EU. The company is still awaiting approval in the New Year.

The vaccine, which has been developed in collaboration with the University of Oxford, together with the Pfizer and Modena vaccines are the most relevant for the EU and therefore Norway, according to the Norwegian Medicines Agency.

Increasing dose

The new tests will be carried out as additional international studies. The goal is to investigate the effect of first administering less than a full dose of the vaccine.

Studies that have been carried out show that the effectiveness of the Oxford vaccine is around 70 percent at a full dose. This is lower than the Pfizer and Modena vaccines, where the efficiency is around 95 percent, according to the BBC.

If the Oxford vaccine is given in two doses, first half a dose and then a full dose, the effectiveness can still increase to 90 percent.

Also read: The enormous loss of researchers may have given us the coronary vaccine that changes everything

Error

But this was discovered as a result of a mistake, according to the US Vaccine Program Differences in the production process have been revealed to mean that some vials contained less vaccine. Therefore, some of the doses were also lower than expected.

The error has raised concerns about routines and processes at AstraZeneca and Oxford, but AstraZeneca has promised that the manufacturing error will be corrected.

(© NTB)

Read more: NIPH calculation: Around 100,000 Norwegians had covid-19

Advertising

Black Friday: here you get a summary of all sales

[ad_2]